Measuring factor IX activity of nonacog beta pegol with commercially available one‐stage clotting and chromogenic assay kits: a two‐center study
- 1 July 2016
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 14 (7), 1428-1435
- https://doi.org/10.1111/jth.13348
Abstract
No abstract availableKeywords
Funding Information
- Physicians World Europe GmbH (Mannheim, Germany)
- Novo Nordisk
This publication has 19 references indexed in Scilit:
- Monitoring of modified factor VIII and IX productsHaemophilia, 2014
- Recommendations on the potency labelling of factor VIII and factor IX concentratesJournal of Thrombosis and Haemostasis, 2013
- Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9‐GP), a glycoPEGylated recombinant factor IXJournal of Thrombosis and Haemostasis, 2012
- Guidelines for the management of hemophiliaHaemophilia, 2012
- Standards and monitoring treatmentHaemophilia, 2012
- Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptideBlood, 2011
- Influence of source of phospholipids for APTT‐based factor IX assays and potential consequences for the diagnosis of mild haemophilia BHaemophilia, 2009
- Assaying the Circulating Factor VIII Activity in Hemophilia A Patients Treated with Recombinant Factor VIII ProductsSeminars in Thrombosis and Hemostasis, 2002
- Influence of phospholipids on the assessment of factor VIII activityHaemophilia, 1998
- In vivo recovery with products of very high purity — assay discrepanciesHaemophilia, 1998